Target intelligence / Profile preview

Eyes absent homolog 2 (EYA2) (EYA2)

Target
EYA2
Molecular classification
Enzyme, Phosphatase, Protein tyrosine phosphatase, Transcription factor, HAD-like phosphatase
01

Overview

Eyes absent homolog 2 (EYA2) is a multi-functional protein that acts as both a transcriptional coactivator and a protein tyrosine phosphatase (UniProt). It is a member of the EYA family, characterized by a highly conserved C-terminal Eya Domain (ED) that exhibits a unique haloacid dehalogenase (HAD)-like phosphatase activity, making it the only known HAD-family member with tyrosine phosphatase function (MDPI, 2021). EYA2 plays a critical role in embryonic development and organogenesis, while in adult tissues, its expression is generally low (GeneCards). However, EYA2 is frequently upregulated in various malignancies, including breast cancer, glioblastoma, and medulloblastoma, where it promotes tumor growth, metastasis, and survival (NIH, 2023). It achieves this by dephosphorylating substrates like H2AX to promote DNA repair over apoptosis and by stabilizing oncoproteins such as MYC (Journal of Experimental Medicine, 2021). Consequently, the EYA2 tyrosine phosphatase domain is a significant therapeutic target, with research focusing on allosteric inhibitors that disrupt its catalytic activity by preventing the binding of essential magnesium ions (NIH, 2021).

Other names
EYA2Eyes absent 2Protein phosphatase EYA2EYA transcriptional coactivator and phosphatase 2
02

Mechanism of action

Allosteric inhibition of the C-terminal haloacid dehalogenase (HAD)-like tyrosine phosphatase domain, which prevents magnesium ion binding and enzymatic activity (NIH, 2021; NIH, 2022).

03

Biological functions

Signal transductionTranscription regulationDNA repairCell proliferationCell migrationOrganogenesisApoptosis regulation
04

Disease associations

CancerMedulloblastomaGlioblastomaBreast cancerOvarian cancerLung cancerProstate cancer
05

Safety considerations

Potential off-target effects on EYA paralogs (EYA1, EYA3, EYA4) (NIH, 2014)Impairment of physiological DNA repair mechanisms (MDPI, 2021)Developmental toxicity due to role in organogenesis (GeneCards)
06

Interacting drugs

Benzarone

4 more in the full profile.

07

Biomarkers

EYA2 overexpression (PubMed, 2023)MYC amplification (NIH, 2023)H2AX-Y142 phosphorylation status (MDPI, 2021)

Beyond the preview

Go deeper on Eyes absent homolog 2 (EYA2) (EYA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyes absent homolog 2 (EYA2) (EYA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call